Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...405406407408409410411412413414415...10671068»
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Expert consensus on drug treatment of chronic subdural hematoma. (Pubmed Central) -  Nov 24, 2021   
    Low-dose and long-term use of atorvastatin (20mg/d) is suggested for continuous treatment for at least 8 weeks, while low-dose and short-term use of dexamethasone can improve the therapeutic effect of atorvastatin on CSDH. Patients should undergo CT or MRI scanning at least one time within 2 weeks after the start of drug treatment.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    Venetoclax 400mg Combined with Bortezomib and Dexamethasone Is Efficacious and Feasible for Plasma Cell Dyscrasia () -  Nov 24, 2021 - Abstract #ASH2021ASH_6957;    
    Among seventeen MM patients, the median follow-up was 9.0 (0.5-27) months and the median treatment cycles was 4 (1-12);fourteen patients have been evaluated for response rate. The overall response rate for evaluable patients (ORR) was 85.7%, among that one patient (7.1%) achieved CR, four patients (28.6%) achieved VGPR and 7 (50%) achieved PR.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Progressive Multifocal Leukoencephalopathy in Multiple Myeloma: A Single Institution Case Series () -  Nov 24, 2021 - Abstract #ASH2021ASH_6950;    
    Patient 1 A 52-year-old male with kappa light chain MM presented in 2009 on hemodialysis and received upfront bortezomib and dexamethasone followed by melphalan 200mg/m 2 and autologous stem cell transplantation (ASCT) in March 2010; maintenance with thalidomide was given until July 2011 when he presented to the ER with left-sided weakness, facial droop, and decreased strength...He was treated with mirtazapine, and also developed status epilepticus controlled with phenytoin and phenobarbital...She commenced cyclophosphamide and prednisone until July 2011 when treatment was changed to lenalidomide and prednisone; subsequent progression in February 2014 was treated with pomalidomide/bortezomib/prednisone...Conclusion Our current series of PML in MM showcases the potential contribution of IMIDs and other novel agents--such as the newer monoclonal antibodies like belantamab mafotidin-- to the reactivation of JC virus and subsequent PML. Our series also demonstrates that neurologic improvement and longer survival can be observed with earlier management.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma () -  Nov 24, 2021 - Abstract #ASH2021ASH_6947;    
    P3
    The median TTNT for this cohort was 8.4 months and median OS was 46.1 months. Conclusions : This retrospective study of non-trial patients with t(11;14) MM provides a benchmark for newer therapies in this patient population for comparison with both venetoclax dexamethasone as well as combinations using the -BortDex backbone.
  • ||||||||||  Northera (droxidopa) / Lundbeck, Sumitomo Dainippon
    Droxidopa for Treatment of Refractory Orthostatic Hypotension in Patients with AL Amyloidosis: A Case Series () -  Nov 24, 2021 - Abstract #ASH2021ASH_6942;    
    Pharmacologic interventions include fludrocortisone, sympathomimetic agents such as midodrine, droxidopa, the acetylcholinesterase inhibitor pyridostigmine or the norepinephrine transporter (NET) inhibitor atomoxetine...Given their poor performance status and advanced organ involvement, none of the patients were eligible for high-dose intravenous melphalan with autologous peripheral blood stem cell transplantation (HDM/SCT), and thus were treated with cyclophosphamide, bortezomib and dexamethasone (CyBorD)...Slow titration may be important to minimize rapid changes in blood pressure. Further studies are warranted to assess droxidopa's safety and compare with other treatments for orthostatic hypotension.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    M-Protein Sequencing and Monitoring in Serum of LC-Only Multiple Myeloma Patients () -  Nov 24, 2021 - Abstract #ASH2021ASH_6934;    
    In the MDACC 2011-0192 frontline study in newly diagnosed MM, transplant-eligible pts received the novel combination of LEN, BTZ, dexamethasone (DEX) and panobinostat (RVD-panobinostat)...To overcome the lower FLC concentration the current study successfully applied LC enrichment strategies to enable the sequencing and high sensitivity monitoring of FLC M-protein by MS in blood. The EasyM LC assay is non-invasive, sensitive, capable of assessing disease status, and has potential to be further investigated as a peripheral blood myeloma response and MRD monitoring biomarker.
  • ||||||||||  Darzalex IV (daratumumab) / J&J, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma () -  Nov 24, 2021 - Abstract #ASH2021ASH_6869;    
    Nine patients have surprisingly achieved a notable response (3 VGPR, 4 PR, 2 MR) after failure of novel agents (i.e. Carfilzomib, Daratumumab and Pomalidomide). Pomalidomide-dexamethasone has shown significant efficacy and a very good compliance, thanks to oral administration, in a particularly severe setting of heavily pretreated patients, relapsed and refractory to all available therapeutic resources, also after failure of novel agents.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome () -  Nov 24, 2021 - Abstract #ASH2021ASH_6855;    
    Case Presentation Our first case is of a 66 year old male with diagnosis of R/R DLBCL, who was treated with R-CHOP, followed by R-GemOx, with no response then received axi cel...At that time, dexamethasone was switched to pulse dose solumedrol and tocilizumab was continued...On day +11, patient's CRS resolved, however ICANS developed to grade 4 and patient received 12 mg intrathecal methotrexate and hydrocortisone 50 mg for steroid-refractory ICANS...It also highlights its importance as an alternative potential therapy to high doses and prolonged courses of corticosteroids which is associated with increased morbidity and mortality. Steroid-refractory ICANS has limited treatment options and further evaluation of the use of IT chemotherapy in large scale studies is warranted.
  • ||||||||||  dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology
    Very-High Dose Dexamethasone Mobilizes Endogenous Bi-Specific Gamma Delta+ NKT Cells () -  Nov 24, 2021 - Abstract #ASH2021ASH_6832;    
    P1/2
    Leukocytosis and lymphocytosis were reported 24 hours post infusion from the B-cell ALL patient but resolved by 7-days without reported intervention. Because a single AVM0703 dose triggers the rapid mobilization and activation of an endogenous bi-specific gamma-delta+ NKT cell with a favorable emerging safety profile, AVM0703 shows promise as a therapeutic agent in treating this serious disease.
  • ||||||||||  Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
    Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients () -  Nov 24, 2021 - Abstract #ASH2021ASH_6785;    
    Therefore, HDACs may promise targets for MM therapy, and panobinostat was approved by FDA for the treatment of relapsed/refractory MM in 2015...Chi-VRd group patients received Chidamide 20mg orally on days -1,2,6 and 9 in combination with VRd (bortezomib 1.3mg/m2 subcutaneously on days 1,4,8,11; lenalidomide 25mg orally on days 1-14; dexamethasone 20mg iv or orally on days 1,2,4,5,8,9,11,12) for 4 cycles...Patients received Chi-VRd get more CR rate. Updated PFS and OS with comparison between VRd and Chi-VRd will be presented at the following study.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study () -  Nov 24, 2021 - Abstract #ASH2021ASH_6687;    
    Prolonged induction with lenalidomide containing regimens does not impair adequate stem cell collection for autologous transplant. Prolonged induction may increase the apheresis time required to collect sufficient stem cells for transplant, but ultimately clinicians should be re-assured that extending induction when necessary is not likely to increase the risk of collection failure.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Refractory Immune Mediated ITP in a Patient with Metastatic Melanoma () -  Nov 24, 2021 - Abstract #ASH2021ASH_6595;    
    Early diagnosis and combination treatment measures early in the course of the disease is imperative to mitigate associated morbidity and mortality. Combination of steroids immunoglobulins and second line agents may be warranted in some cases, and earlier use of tier 2 agents such as azathioprine should also be considered.
  • ||||||||||  Melflufen (melphalan flufenamide) / Oncopeptides, Darzalex IV (daratumumab) / J&J
    Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity () -  Nov 24, 2021 - Abstract #ASH2021ASH_6592;    
    Our preclinical study showed that melflufen is a more potent anti-myeloma (MM) agent than melphalan, overcomes drug-resistance, and induces synergistic anti-MM activity in combination with bortezomib, lenalidomide, or dexamethasone (Chauhan et al, Clinical Cancer Res 2013;19:3019 )...Here, we utilized our coculture models of pDCs, T-, and NK cells with autologous patient MM cells to examine whether a combination of melflufen and immune checkpoint inhibitor anti-PD-L1 Ab, or daratumumab (anti-CD38 Ab), restores anti-MM immunity...Moreover, combined melflufen and anti-CD38 Abs modestly enhance pDC-induced NK cell-mediated MM-specific cytolytic activity. Our preclinical data suggest targeting PD-L1 in combination with melflufen as well as support an ongoing clinical trial of melflufen with anti-CD38 Abs to enhance anti-MM immunity.
  • ||||||||||  dexamethasone / Generic mfg.
    Autoimmune Cytopenias and Covid-19 Vaccination: Relapse and Suggested Treatment () -  Nov 24, 2021 - Abstract #ASH2021ASH_6571;    
    The viral protein spike from SARS-Cov2 has mimicry between the Ankyrin-1 in the erythrocyte surface, and has been linked as one of the pathogenesis pathways of autoimmune hemolytic anemia secondary to COVID-19 (Br J Haematol 2020;190:e92-e93 and Blood 2020;136:suppl8,138001). Relapse of autoimmune cytopenias after vaccination with SARS-Cov2 involves stimulation of autoantibodies production from preexisting B cells.
  • ||||||||||  dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology
    AVM0703 Tumor Debulking Enhances Cy/Flu Efficacy () -  Nov 24, 2021 - Abstract #ASH2021ASH_6503;    
    AVM0703 has the potential to be one solution when used in combination with chemotherapy. Future clinical trials will determine if debulking with AVM0703 results in a reduction of the number of necessary R-CHOP cycles while maintaining or enhancing the efficacy rate.
  • ||||||||||  dexamethasone / Generic mfg., mercaptopurine / Generic mfg., zoledronic acid / Generic mfg.
    Influence of Bisphosphonates or Recombinant Human Parathyroid Hormone on in Vitro Chemotherapy Sensitivity in Acute Lymphoblastic Leukemia Cells () -  Nov 24, 2021 - Abstract #ASH2021ASH_6470;    
    Nevertheless, our findings suggest a minimal effect of pamidronate on DEXA-induced leukemia cell death. This suggests that even though zoledronate or pamidronate do not seem to negatively influence DEXA- or PRED- induced toxicity in expected physiological concentrations (one- to three-fold physiological peak plasma concentrations), these bone-modifying agents may only be considered with caution in individual cases, and preferably in clinical trial settings before being applied on a large scale in children with ALL.
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma () -  Nov 24, 2021 - Abstract #ASH2021ASH_6460;    
    ISS was equally distributed, and all patients had previously been treated with bortezomib and IMIDs, and were refractory to this agents...Carfilzomib was well tolerated, with grade 2 anemia in 39%(16/41) of patients, successfully managed by ESAs, without necessity of blood transfusions; 29% (12/41) grade 3-4 neutropenia (pegfilgrastim in primary prophylaxis was given, no ospedalization was required, no septic shocks were observed); 34% (14/41) grade 2, 21% (9/41) grade 3 and 12% (5/41) grade 4 thrombocytopenia, without hemorrhagic events and transfusion-dependency...A cardiac monitoring was performed for all patients: hypertension (grade 2-3) in 34% (14/41) of patients; fatigue in 39% (16/31) of patients. Carfilzomib-Lenalidomide-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, also lenalidomide, and it could be considered as a bridge to a second autologous or allogenic SCT.
  • ||||||||||  dexamethasone / Generic mfg.
    Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program () -  Nov 24, 2021 - Abstract #ASH2021ASH_6431;    
    From September 2019 to May 2021, 20 patients (19 adults and 1 child) received commercial CAR T-cell products: 13 axicabtagene ciloleucel (axi-cel) for diffuse large B-cell lymphoma (DLBCL), 6 tisagenlecleucel (tisa-cel) (3 for ALL and 3 for DLBCL), 1 brexucabtagene autoleucel (brex-cel) for mantle cell lymphoma...Seven patients (39%) received an IL-6 inhibitor with a median of 1 dose (range 1-5) and 7 received dexamethasone for a median duration of 4 days (range 1-21)...Outpatient administration and management of CAR T-cell therapy was safe and feasible with our approach. With the ongoing expansion of new indications for CAR T-cell products, strategies for safe outpatient administration are relevant to the practical clinical utility of these therapies.
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant () -  Nov 24, 2021 - Abstract #ASH2021ASH_6423;    
    Our real-world data showed that GDP/GDCarboP provides meaningful efficacy and response durability in a third of these difficult-to-treat patients with median 2 prior lines of treatment and who were ineligible for SCT. More than half of these patients had required dose modification, blood transfusion, and hospital admission, indicating the need for good supportive care and close follow-up during treatment, even though this is an outpatient regimen.